Partner Kathleen Sanzo, a leader in our life sciences practice, spoke with Corporate Counsel on the uncertainty surrounding how the Food and Drug Administration will regulate CBD in food. Kathy says in the article that rule-making will likely take many years and that attention will be paid to the supply chain of products.
Read the full Corporate Counsel* article. (subscription may be required)